Ovid Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
OVID Nasdaq 2836 www.ovidrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ovid Therapeutics Inc.

Promising Penny Stocks To Watch In December 2025 - Dec 26th, 2025 5:04 am
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) - Dec 18th, 2025 6:00 am
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer - Dec 2nd, 2025 5:00 am
November 2025's Top Penny Stock Opportunities - Nov 27th, 2025 11:04 am
Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates - Nov 12th, 2025 6:10 am
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results - Nov 12th, 2025 5:00 am
Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data - Nov 12th, 2025 3:20 am
QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer - Nov 10th, 2025 5:45 am
MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates - Nov 5th, 2025 7:15 am
AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates - Nov 4th, 2025 3:50 pm
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Nov 4th, 2025 8:00 am
B. Riley Lifts Ovid Therapeutics (OVID) PT to $5 on Strong OV329 Phase 1 Data - Oct 26th, 2025 4:05 am
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - Oct 10th, 2025 8:27 am
Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says - Oct 9th, 2025 8:59 am
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know - Oct 6th, 2025 10:00 am
Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results - Oct 4th, 2025 7:43 am
Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Investors Eye Another Interest Rate Cut for 2025 - Oct 3rd, 2025 7:24 am
Sector Update: Health Care Stocks Advance Premarket Friday - Oct 3rd, 2025 7:19 am
Investors Cautious as Government Shutdown Persists, Driving Muted Premarket Action for US Equity Futures - Oct 3rd, 2025 7:04 am
Ovid Therapeutics Agrees to Financing Deal Worth up to $175 million - Oct 3rd, 2025 5:56 am